Group 1 - The company reported a 5.5% growth in comparable sales for the first quarter, marking the fourth consecutive quarter of positive growth [4] - The North American business demonstrated resilience despite a complex macroeconomic environment [4] - The CEO highlighted the successful execution of strategic initiatives contributing to the positive performance [4] Group 2 - The conference call included forward-looking statements regarding the company's business outlook [2] - The CFO will provide detailed financials and outlook for the remainder of the year [3]

Financial Data and Key Metrics Changes - Total revenues for the first quarter were $386.9 million, a 4% increase year over year [7] - Adjusted EBITDAre was $75.1 million, up 17% year over year [7] - Normalized FFO was $14.3 million or $0.06 per share, exceeding analyst consensus estimates [7] - Same property cash basis NOI was $71.5 million, representing a 20.7% increase year over year [16] Business Line Data and Key Metrics Changes - In the SHOP sector, same property NOI was $38.4 million, a 33.6% sequential increase and a 42.1% year over year increase [8] - Average monthly rate in the SHOP segment increased by 4.8% year over year, with occupancy rising by 130 basis points to 80.2% [9] - Medical office and life science portfolio saw same property occupancy at 90.1%, down 10 basis points from the previous quarter [10] Market Data and Key Metrics Changes - The company completed approximately 145,000 square feet of new and renewal leasing activity in the medical office and life science portfolio, with weighted average rents 18.4% higher than prior rents [10] - Known vacates in the medical office building and life science portfolio for 2025 are modest at 115,000 square feet [11] Company Strategy and Development Direction - The company completed $332 million in asset sales to address upcoming debt maturities and deleverage the balance sheet [7] - The active disposition pipeline includes 65 properties, with expected proceeds between $350 million and $400 million [13] - The company aims to enhance portfolio performance by focusing on well-positioned SHOP assets and best-in-class triple net MOB and life science properties [14] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting 2025 and 2026 debt maturities, with no debt maturities until 2028 thereafter [22] - The company reaffirmed its 2025 SHOP NOI guidance range of $120 million to $135 million, with potential for increase based on trends [23] Other Important Information - The company invested approximately $32 million in capital during the quarter, with $27 million in SHOP communities and $5 million in the medical office and life science portfolio [17] - The company highlighted the publication of the RMR Group's annual sustainability report, showcasing its commitment to sustainability across its portfolio [14] Q&A Session Summary Question: Can you provide some color on the occupancy gains for the first quarter? - Management noted that occupancy improved due to capital investments in communities and operational initiatives [25][26] Question: Is the Aleris Life dividend a one-time payment? - Management indicated that it was more of a one-time dividend, but future dividends could be possible depending on Aleris's performance [27] Question: Why is the SHOP guidance not increased despite strong NOI performance? - Management explained that business interruption proceeds impacted the current quarter's NOI and that they are awaiting clarity on disposition timing [29][31] Question: Any specific reasons for flat operating expenses in SHOP? - Management stated that operating expenses were flat sequentially, with a year-over-year increase of about 3%, and noted savings in insurance premiums [36][37] Question: What are the expectations for pricing on upcoming financings? - Management expects a weighted average interest rate of about 6.5% for upcoming financings, which is favorable compared to existing debt [41]